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costs of aggregate back pain were $14,701,417,650,
work-related back pain were $2,643,650,647, and missed
workdays back pain were $5,396,355,220. With regard
to aggregate back pain, higher proportions of direct costs
were incurred for ofﬁce-based medical provider visits at
$5,768,302,826 (mean = $68; 95% C.L. = $61 to $75),
inpatient visits at $4,658,655,867 (mean = $10,016; 
95% C.L. = $9,463 to $10,570), and outpatient visits 
at $2,050,207,343 (mean = $274; 95% C.L. = $204 to
$345). Lower proportions of direct costs were incurred
for prescriptions, home health visits, and emergency room
visits. CONCLUSIONS: Direct costs associated with
back pain are sizable. As direct costs of occupationally
related back pain were substantially lower than total
direct costs of $14.7 billion, Workman’s Compensation
claims may underestimate the true impact of back pain
on medical care utilization and expenditure.
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OBJECTIVES: To estimate the socio-economic burden of
migraine by calculating the direct and indirect costs of the
disease. METHODS: The prevalence approach was used
to calculate the annual direct (pharmacy, specialist and
primary care consultations, emergency room visits) and
indirect (missed workdays and reduced performance at
work) costs of migraine in Spain in 2001. Data was
extracted from published epidemiological and resource
use studies which used the International Headache
Society diagnostic criteria and from publicly available
ofﬁcial and unofﬁcial databases. The indirect costs were
calculated by the human capital approach using the
model developed by Hu XH et al. RESULTS: The current
Spanish population suffering from migraine was esti-
mated at 3,617,600 patients of whom 92.5% were of an
age to work. The economic burden of migraine was
greater than €1500 million. The direct costs represented
only 21.9% of the total burden (€331 million), of which
40.7% was attributable to primary care ofﬁce visits,
29.8% to specialist consultations, 17.3% to emergency
room visits and a further 12.1% to migraine-speciﬁc 
prescription drugs (triptans 11.2%, ergots 0.9%). The
indirect cost was estimated at €1177 million annually,
which represents a cost per working migraine-sufferer of
€729.46. Most indirect costs (almost €660 million) were
due to migraine-related missed workdays. CONCLU-
SIONS: As in many other developed countries, migraine
puts a considerable economic burden on Spanish society,
especially in terms of work losses. Therefore, activities
should be aimed speciﬁcally at reducing the indirect costs
of the disease, and effective treatments, which have
demonstrated a signiﬁcant reduction in work losses,
should be publicly promoted.
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OBJECTIVES: Epilepsy is one of the most frequent neu-
rological disorders. One-third of epileptic patients suffer-
ing from partial onset seizures cannot be satisfactorily
controlled despite the availability of a large number of
anti-epileptic drugs. The present study reports on an eco-
nomic evaluation of Levetiracetam (LEV) used as an add-
on therapy in refractory epileptic patients. METHODS:
A cost-effectiveness analysis was done using data derived
from three randomised clinical trials. A dose escalation
decision model comparing LEV add-on to standard
therapy alone was designed. Total treatment cost esti-
mates were based on seizure-related costs, routine follow-
up of patients, cost of adverse events as well as LEV
acquisition cost. The perspective is that of the Ontario
(Canada) Ministry of Health. As time horizon for the esti-
mation of costs is one year, no discounting was applied.
Treatment effectiveness was measured by the number 
of seizure free days gained (SFDs). Extensive sensitivity
analyses were performed to test the robustness of the
results, including inclusion of the costs of pre-surgical
evaluation and surgery in addition to the other costs.
RESULTS: Total treatment cost per patient per year was
estimated at Canadian dollars (CAD) 3925 for LEV 
add-on and at CAD 2404 for maintenance of standard
therapy—the difference was mainly related to drug acqui-
sition costs. LEV add-on was associated with an incre-
mental gain of 19 SFDs per patient per year. As such, the
incremental cost effectiveness ratio was CAD 80.7 per
seizure free day gained. When costs associated with pre-
surgical evaluation and surgery were considered, the LEV
add-on approach was in a dominant situation leading to
cost savings of CAD 5871 per patient per year. CON-
CLUSIONS: This economic evaluation demonstrates that
Levetiracetam add-on is a cost-effective alternative to
maintenance of standard therapy for the treatment of
refractory epilepsy.
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OBJECTIVES: Topiramate as add-on treatment is 
effective in patients with refractory epilepsy. Since there
has been less research aimed at evaluating its cost-
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effectiveness, we conducted a retrospective lifetime cost-
utility analysis. METHODS: Effectiveness data were
derived from a pivotal placebo-controlled clinical trial,
while utility and cost data were retrieved from published
information. Our pharmacoeconomic model was similar
to that employed in a previous study on lamotrigine (Eur
J Clin Pharmacol 1998;53:421), but used UK cost-of-
illness data. In the ﬁrst analysis, aggregated data on effec-
tiveness were used (clinical endpoint = number of patients
with 50% or more reduction in seizure frequency) allow-
ing a direct comparison between lamotrigine and topira-
mate. Our second analysis was based on individual
patient data from the topiramate trial (clinical endpoint
= individual values of reduction in seizure frequency).
Both analyses were intention-to-treat. RESULTS: The
analysis based on aggregated data showed that topira-
mate (200mg/day) implies an incremental lifetime cost of
£350,326 and a utility of 90 quality-adjusted life-years
(QALYs) for every 100 patients. The same ﬁgures for lam-
otrigine (500mg/day) were £1,324,295 and 58 QALYs,
respectively (discounted values, yearly rate = 3%, year of
costing = 2001). The cost-utility ratio was £3,893 per
QALY gained for adjunctive topiramate as opposed to
£22,833 for lamotrigine, both compared to add-on
placebo. Sensitivity testing suggested a range of £3,129
to £4,870 and of £14,175 to £45,841 for topiramate and
lamotrigine, respectively. Our analysis based on individ-
ual data showed that topiramate compared to placebo
implies an incremental lifetime cost of £1,024,941 and a
utility of 48 QALYs for every 100 patients. The cost
utility ratio is £21,353 per QALY gained. CONCLU-
SIONS: Our results show that, in refractory epilepsy,
adjunctive topiramate has a favourable pharmacoeco-
nomic proﬁle. In this analysis, using aggregated clinical
information generated more optimistic values of cost
effectiveness than using individual patient data.
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OBJECTIVE: To evaluate the clinical utilization of
Dysport and BOTOX for cervical dystonia and ble-
pharospasm. Botulinum toxin (BTX) is safe and effective
therapy for cervical dystonia and blepharospasm. Two
serotype-A toxins, Dysport and BOTOX, are widely pre-
scribed, yet actual clinical utilization is poorly deﬁned or
understood. Previous efforts to compare products have
been limited by sample size or study designs that mandate
drug usage according to protocol. Utilization in actual
clinical practice is more appropriate to determine the true
effective dose and dose ratios. METHODS: Two sites
where BTX is prescribed for cervical dystonia and ble-
pharospasm were identiﬁed in the UK (Bristol and Hull)
as part of a retrospective observational study. Each 
site culled BTX data from medical records of patients
who received Dysport before switching to BOTOX.
RESULTS: Assessment of 29 patients (14 cervical dysto-
nia, 15 blepharospasm) provided a total of 456 injections
for computation of mean dose, which was 839.6 ± 308.5
units (Dysport) versus 162.8 ± 64.9 units (BOTOX) for
cervical dystonia; and 109.9 ± 33.9 units (Dysport) versus
23.5 ± 8.0 units (BOTOX) for blepharospasm. The ratios
of mean dose ranged from 2 :1 (Dysport to BOTOX
units) to 9 :1 (Dysport to BOTOX units), with over 
79% of patients utilizing a ratio >4:1. When current
pricing for Dysport (£164.74/500 units) and BOTOX
(£128.93/100 units) is applied, incremental costs of
£66.68/patient and £5.90/patient were incurred with
Dysport for cervical dystonia and blepharospasm respec-
tively. CONCLUSION: Results demonstrate that no one
ratio exists between Dysport and BOTOX, consistent
with the UK labeling: units of different serotype-A toxins
are not interchangeable and comparisons based on simple
dosage conversion factors are not applicable. Current
pricing suggests incremental cost savings with BOTOX,
other outcomes, including adverse events, also should 
be considered to better understand the overall costs and
consequences of treatment.
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OBJECTIVE: To examine the impact of glatiramer
acetate (GA) versus beta interferons 1a (1A) and 1b (1B)
on relapse rates as well as utilization and costs among
patients with multiple sclerosis (MS) in a managed care
setting. METHODS: Data were obtained from a national
retrospective database of patient-linked medical and
pharmacy claims from January 1996 to June 2001.
Patients were followed from the ﬁrst prescription for
immunomodulatory therapy until plan disenrollment or
end of study timeframe. The incidence of all relapses
(deﬁned as hospitalization for MS or ambulatory visit fol-
lowed by use of systemic corticosteroids) as well as uti-
lization and costs of MS-related care were examined for
each group. Data were adjusted for variable follow-up
using survival techniques; the risk of relapse was evalu-
ated using a Cox proportional hazards model. RESULTS:
A total of 8,457 patients receiving immunomodulatory
therapy were included in the study cohort (1,674, 5,031,
and 1,752 for GA, 1A, and 1B respectively); follow-up
averaged 17.3 months. Three-quarters of patients were
female; the mean age was 42.2 years. The risk of relapse
at one year post-therapy initiation was signiﬁcantly
increased for the beta interferons relative to GA (hazard
